HCA

HCA Healthcare, Inc. - 10-Q Filing Summary

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for HCA Inc. (HCA), a holding company owning and operating hospitals and related health care entities. The report covers the quarterly and six-month periods ended June 30, 2002. As of this date, HCA's affiliates operated 175 hospitals and 75 freestanding surgery centers across 23 U.S. states, England, and Switzerland.

Key Financial Metrics

Note: Adjusted Net Income excludes goodwill amortization, which ceased under SFAS 142 effective Jan 1, 2002.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 9.5% in Q2 2002 and 8.9% for the six months ended June 30, 2002, compared to the prior year. This was driven primarily by an 8.1% increase in revenue per equivalent admission in Q2, attributed to favorable managed care contract renewals and government reimbursement improvements.
• Profitability: Income before taxes rose 35.0% in Q2 and 24.1% for the six-month period. Pretax margins improved to 11.9% in Q2 from 9.6% in the prior year.
• Expense Management: Salaries and benefits decreased as a percentage of revenue to 40.0% in Q2 from 40.7% in 2001. Other operating expenses dropped to 16.8% of revenue from 18.1%.
• Bad Debts: The provision for doubtful accounts increased to 7.6% of revenue in 2002 from 6.7% in 2001, largely due to rate increases on self-pay and uninsured patients.
• Interest Expense: Interest expense declined to $108 million in Q2 from $139 million in 2001, reflecting lower interest rates and an improved credit rating.

Guidance, Outlook, Risks, and Unusual Items

• Government Investigations & Settlements: HCA remains subject to ongoing federal investigations (DOJ, SEC) and litigation regarding business practices. A $250 million settlement with CMS regarding Medicare cost reports was reached in March 2002 (accrued in 2001) but awaits DOJ approval. Outstanding civil issues regarding cost reports and physician relations remain unresolved, with potential liabilities that could be material.
• Unusual Items:
  • Impairment Charge: A non-cash, pretax charge of $19 million was recorded in Q2 2002 for the impairment of long-lived assets related to delayed ERP system components.
  • Investigation Costs: $13 million in investigation-related costs were incurred in Q2 2002, primarily for legal and accounting fees.
• Capital Allocation: HCA announced a new authorization in July 2002 to repurchase up to 12 million shares of common stock. Annual planned capital expenditures are projected at approximately $1.7 billion for 2002.
• Outlook: Management anticipates continued revenue growth driven by volume and pricing but faces challenges from payment pressure and the need to control costs. The company expects to meet liquidity needs through operating cash flows and its $2.5 billion credit facility.

Investor Verification Checklist

• Legal Contingencies: Verify the status of the $250 million CMS settlement approval and the potential exposure from remaining DOJ civil issues (cost reports/physician relations) and SEC investigations.
• Bad Debt Trends: Monitor the increasing provision for doubtful accounts (7.6% of revenue) and its impact on net margins, particularly regarding self-pay patient rates.
• Debt Structure: Review the impact of the new $500 million 6.95% notes issued in April 2002 and the company's ability to service its ~$7.2 billion total debt load.
• Capital Expenditures: Assess the $2.5 billion in projects under construction and the company's ability to fund the projected $1.7 billion annual capex without diluting equity or increasing leverage significantly.
• Accounting Changes: Confirm the impact of SFAS 142 adoption (elimination of goodwill amortization) on future earnings comparisons.